Please ensure Javascript is enabled for purposes of website accessibility

Why Gilead Sciences Stock Is Up 13% Today

By George Budwell – Updated Feb 3, 2020 at 10:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's shares are jumping this morning after the announcement of a coronavirus research agreement in China. Time to buy?

What happened

Biotech blue blood Gilead Sciences (GILD 1.02%) saw its shares jump by as much as 13% in pre-market action Monday morning. The stock perked up in response to a research agreement with Chinese authorities to begin a clinical trial of the antiviral medication remdesivir in patients infected with the novel coronavirus known as 2019-nCoV. The trial will reportedly take place in Wuhan, China, the epicenter of the current outbreak. 

So what

The coronavirus has already killed 361 individuals, based on the latest figures from the World Health Organization. And it has quickly spread from China to neighboring Asia-Pacific nations, North America, Europe, and the Middle East. If a viable treatment isn't identified soon, the death toll from this unique respiratory disease could skyrocket in the coming weeks.

A test tube labeled "coronavirus".

Image source: Getty Images.

In fact, the challenging circumstances developing in Wuhan might be skewing the actual infection rates by health authorities in the region. Put simply, this outbreak might actually be far worse than current estimates suggest. What this all means is that health authorities in China and elsewhere may be forced to take extraordinary measures soon, such as approving novel treatments like Gilead's antiviral remdesivir in record time.  

Now what

Should investors take advantage of this rapidly developing healthcare story? While there's a growing chance that this may in fact be a boon for one or more biotechs at the end of the day, it's still a long shot. Gilead (or any other coronavirus player for that matter) is highly unlikely to get a marketing approval for a coronavirus treatment before the outbreak simply peters out. In short, this breaking news story is not a solid reason to buy this top biotech stock today.  


George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.32 (1.02%) $0.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.